Cantor Fitzgerald reiterated their buy rating on shares of Healthequity (NASDAQ:HQY) in a research note issued to investors on Tuesday. They currently have a $56.00 price objective on the stock.

A number of other equities research analysts have also weighed in on HQY. Zacks Investment Research upgraded shares of Healthequity from a hold rating to a buy rating and set a $58.00 price objective for the company in a report on Wednesday, October 11th. BidaskClub lowered shares of Healthequity from a hold rating to a sell rating in a report on Wednesday, October 18th. Oppenheimer restated a buy rating and issued a $61.00 price objective on shares of Healthequity in a report on Wednesday, September 6th. Robert W. Baird restated a hold rating on shares of Healthequity in a report on Thursday, September 21st. Finally, Chardan Capital boosted their price objective on shares of Healthequity from $58.00 to $62.00 and gave the stock a buy rating in a report on Wednesday. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $58.33.

Shares of Healthequity (HQY) traded down $0.37 during trading on Tuesday, reaching $48.49. 516,400 shares of the company’s stock traded hands, compared to its average volume of 522,736. Healthequity has a twelve month low of $37.62 and a twelve month high of $55.31. The company has a market capitalization of $2,955.48, a price-to-earnings ratio of 77.56, a PEG ratio of 2.14 and a beta of 1.74.

Healthequity (NASDAQ:HQY) last announced its earnings results on Tuesday, December 5th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.04. Healthequity had a net margin of 20.27% and a return on equity of 13.93%. The business had revenue of $56.80 million during the quarter, compared to analyst estimates of $55.27 million. During the same period in the previous year, the business posted $0.10 earnings per share. Healthequity’s revenue for the quarter was up 31.0% on a year-over-year basis. analysts expect that Healthequity will post 0.7 EPS for the current fiscal year.

In related news, insider Stephen Neeleman sold 8,500 shares of Healthequity stock in a transaction on Friday, September 15th. The shares were sold at an average price of $45.24, for a total value of $384,540.00. Following the transaction, the insider now directly owns 1,000 shares of the company’s stock, valued at $45,240. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Darcy G. Mott sold 9,500 shares of Healthequity stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $46.79, for a total transaction of $444,505.00. Following the completion of the transaction, the vice president now directly owns 87,500 shares in the company, valued at $4,094,125. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,733,212 shares of company stock worth $90,635,651. 19.00% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Zions Bancorporation purchased a new position in Healthequity during the 3rd quarter valued at $119,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Healthequity by 105.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,544 shares of the company’s stock valued at $127,000 after purchasing an additional 1,308 shares during the period. Riverhead Capital Management LLC increased its position in Healthequity by 75.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,629 shares of the company’s stock valued at $131,000 after purchasing an additional 1,129 shares during the period. Oppenheimer Asset Management Inc. increased its position in Healthequity by 7.7% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 2,686 shares of the company’s stock valued at $134,000 after purchasing an additional 191 shares during the period. Finally, Fortaleza Asset Management Inc. purchased a new position in Healthequity during the 2nd quarter valued at $138,000. 98.60% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Healthequity’s (HQY) “Buy” Rating Reaffirmed at Cantor Fitzgerald” was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/12/06/healthequitys-hqy-buy-rating-reaffirmed-at-cantor-fitzgerald.html.

About Healthequity

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Analyst Recommendations for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity Inc and related companies with MarketBeat.com's FREE daily email newsletter.